Jan 9 (Reuters) - Krystal Biotech Inc :
* KRYSTAL BIOTECH ANNOUNCES FDA’S 3-MONTH EXTENSION OF BLA PDUFA DATE AND REGULATORY UPDATE FOR B-VEC TO TREAT PATIENTS WITH DYSTROPHIC EPIDERMOLYSIS BULLOSA
* KRYSTAL BIOTECH INC - PDUFA DATE HAS BEEN REVISED TO MAY 19, 2023, AND PROPOSED LABELING DISCUSSIONS TO NO LATER THAN APRIL 20, 2023
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。